-
Product Insights
New![]()
Net Present Value Model: GSK plc’s LiProSal
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. GSK plc's LiProSal Drug Details: Liprosal is under development for the treatment of bipolar disorder, major depressive disorder, post traumatic stress disorder (PTSD), dementia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AL-001 in Alzheimer’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-001 in Alzheimer's Disease Drug Details: Liprosal is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AL-001 in Dementia Associated With Alzheimer’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-001 in Dementia Associated With Alzheimer's Disease Drug Details: Liprosal is under development for...
-
Company Insights
NewLegal and General (L&G) – Digital Transformation Strategies
Legal & General (L&G) Digital Transformation Strategies Report Overview Legal & General (L&G) has been focusing on emerging technologies as a part of its digital transformation strategies. The annual ICT spending of L&G was estimated at $391.9 million in 2022. A major share of this spending is earmarked for acquiring software, hardware, and consulting from vendors. L&G provides insurance, saving, and investment products, it offers individual and group protection plans, annuities, mortgages, pension plans, and general insurance products. Total ICT...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Gastric Cancer Drug Details: Bis5 (LB-1410) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Anal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Anal Cancer Drug Details: Bis5 (LB-1410) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Non-Small Cell Lung Cancer Drug Details: Bis5 (LB-1410) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Ovarian Cancer Drug Details: Bis5 (LB-1410) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Endometrial Cancer Drug Details: Bis5 (LB-1410) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Solid Tumor Drug Details: Bis5 (LB-1410) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Colorectal Cancer Drug Details: Bis5 (LB-1410) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: Bis5 (LB-1410) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Small-Cell Lung Cancer Drug Details: Bis5 (LB-1410) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Lymphoma Drug Details: Bis5 (LB-1410) is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Head And Neck Cancer Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: Bis5 (LB-1410) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.OTL-203 in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )Drug Details:OTL-203 is under development for the treatment...
-
Thematic Analysis
New![]()
Mining Industry Mergers and Acquisitions Deals by Top Themes in Q2 2023 – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q2 2023 in the Mining Sector
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rigosertib sodium in Metastatic Melanoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rigosertib sodium in Metastatic Melanoma Drug Details: Rigosertib (Estybon, ON 01910.Na and SyB L-1101)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rigosertib Sodium in Epidermolysis Bullosa
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rigosertib sodium in Epidermolysis Bullosa Drug Details: Rigosertib (Estybon, ON 01910.Na and SyB L-1101)...
-
Thematic Analysis
New![]()
Consumer Goods Industry Mergers and Acquisitions Deals by Top Themes in Q2 2023 – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q2 2023 in the Consumer Goods Sector
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.